Chai Discovery
AI biomolecular design and structure prediction company
Chai Discovery is a biotechnology company that develops AI models for predicting and designing the three-dimensional structure of biomolecules, including proteins, nucleic acids, and their complexes with small molecules, extending the line…
Definition
Chai Discovery is a biotechnology company that develops AI models for predicting and designing the three-dimensional structure of biomolecules, including proteins, nucleic acids, and their complexes with small molecules, extending the line of research popularized by structure-prediction systems like AlphaFold toward practical drug and biomolecule design applications. It is known for releasing versions of its structure prediction model, Chai-1 and successors, with some components made openly available to the research community alongside a commercial offering.
Overview
Chai Discovery works in the research area that opened up after AlphaFold demonstrated that deep learning could predict a protein's three-dimensional structure from its amino acid sequence with striking accuracy, a result that reshaped structural biology. Where AlphaFold and its direct successors focused primarily on single-protein structure prediction, Chai Discovery's stated goal is to extend similar modeling techniques toward broader biomolecular design tasks: predicting how proteins interact with other proteins, nucleic acids, and small-molecule ligands, which is more directly relevant to drug discovery than isolated structure prediction alone. Mechanically, Chai Discovery's models are deep learning systems, drawing on architectures related to those used in modern protein structure prediction, trained on large datasets of known biomolecular structures to predict complexes involving multiple interacting molecules simultaneously rather than a single folded protein in isolation. This multi-molecule complex prediction is technically more demanding than single-protein folding because it requires modeling how binding at one site can influence structure elsewhere, and because training data for such complexes is comparatively scarcer than data for individual protein structures. Within the growing ecosystem of AI structure prediction tools, Chai Discovery positions itself between fully open academic research projects and fully closed commercial platforms, having released model weights and code for research use for some versions while building a separate paid platform aimed at pharmaceutical and biotech customers seeking structure prediction as part of their drug discovery workflow. This hybrid open-then-commercial strategy distinguishes it from companies like Isomorphic Labs, which has kept its structure prediction technology proprietary from the outset, while still monetizing the underlying capability. In practice, researchers and drug discovery teams use Chai Discovery's models to predict how a candidate small molecule or antibody might bind to a target protein, informing which candidates are worth pursuing experimentally, and to explore protein-protein or protein-nucleic-acid interactions relevant to a given disease mechanism. This kind of structure prediction is typically one input among several in a broader discovery pipeline rather than a standalone drug discovery product. The limitations mirror those of the broader structure prediction field: predicted structures and binding poses are estimates that can be wrong, particularly for the harder cases of flexible proteins, novel interaction types not well represented in training data, or complexes with more than a couple of interacting molecules. As with other computational prediction tools, results generally need experimental validation, such as crystallography or cryo-electron microscopy, before being relied upon for major drug development decisions.
Key Features
- Deep learning models predicting multi-molecule biomolecular complexes
- Extends structure prediction beyond single proteins to protein-ligand interactions
- Released model versions (Chai-1 and successors) partly open for research
- Separate commercial platform for pharmaceutical and biotech customers
- Builds on architectural advances from protein structure prediction research
- Targets protein-protein and protein-nucleic-acid interaction prediction
- Positioned as one input within broader drug discovery workflows
Use Cases
Alternatives
Frequently Asked Questions
From the Blog
AI in Healthcare: Opportunities and Risks in 2026
AI is being used in radiology, drug discovery, clinical documentation, and patient triage — and it's raising serious questions about bias, accountability, and patient safety. This guide gives developers and healthcare professionals an honest overview of where AI helps, where it harms, and what responsible deployment looks like.
Read More ProgrammingPytest fixtures explained: scope, teardown and conftest
Fixture scope is a correctness decision before it is a speed one. This walks through what each of the four scopes shares, why the yield form is the right way to tear down, how conftest.py discovery decides which tests can see a fixture, and how shared mutable state turns a green suite order-dependent.
Read More